Keith Thompson (CGT) announces the creation of Islexa

On day 1 of the World Stem Cells & Regenerative Medicine Congress, Keith Thompson, CEO of the Cell and Gene Therapy Catapult, announced, in partnership with the University of Aberdeen, the creation of a new company: Islexa. Islexa is developing an innovative method to produce laboratory grown islets, which are the organoids in charge of insulin production. This technology holds …

Rock and roll years of regen med

Guest Blog: The rock and roll years for regenerative medicine

This year (2015) marks the tenth anniversary for the Terrapinn World Stem Cells &  Regenerative Medicine Congress, but the question in my wind is how far has this industry travelled in those years. Returning to this conference for the third year and now with more than ten years involvement in the sector I hope to answer my own question over …

World Stem Cells & Regenerative Medicine Congress 2015

Leading industry insights from stem cells & regenerative medicine professionals

This May 20th, London will welcome over 60 leading international speakers to the 10th annual World Stem Cells & Regenerative Medicine Congress. Ahead of then we wanted to give you a taste of what you will hear on-site with some exclusive insights from these esteemed thought-leaders. Click here to read the full speaker interviews as part of the Industry Insights …

Enabling Cell Therapy: Case Study on Scaling-Up Allogeneic Stem Cell Manufacturing From Multi-Tray Stacks To the Xpansion® MultiplateBioreactor

Sarah Snykers and Dr. Jose Castillo, Pall Life Sciences joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to discuss ‘Enabling Cell Therapy: Case Study on Scaling-Up Allogeneic Stem Cell Manufacturing From Multi-Tray Stacks To the Xpansion® MultiplateBioreactor.’ Download this presentation now to find out: Promethera® Biosciences • Who we are? • Our process & product …

regenerate the human body

Can we really regenerate the human body from head to toe?

As news hits the stand that next May will see the ‘world’s first 3D-bioprinted organ transplantation’ take place with a thyroid gland, we take a look at a selection of other regeneration projects from across the globe that are working towards regenerating parts of the human body ahead of the tissue engineering and organ regeneration track at the World Stem …

Can cell therapy become the next generation of biological therapeutic products?

Zami Aberman, Chairman and Chief Executive Officer, Pluristem joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present ‘Can cell therapy become the next generation of biological therapeutic product?’ Download this presentation now to find out: Can cell therapy become the next generation of biological therapeutic products? Cell therapy “must haves” to become the next biological …

Clinical development planning needed for an effective product launch

Sven Kili, Senior Director, International Medical Affairs – Biosurgery, Sanofi joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present on ‘Clinical development planning for an effective launch.’ Download this presentation now to find out: Designing a clinical trial programme to support planned commercialisation Launch Strategies and timing Post-marketing activities –including Key Opinion Leader Management …

Identifying unique manufacturing challenges of Auto vs Allo cell based therapies

Dr Stephen Ward, Chief Operating Officer, Cell Therapy Catapult joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present on ‘Identifying unique manufacturing challenges of Auto vs Allo cell based therapies.’ Download this presentation now to find out: UK Regenerative Medicine Context Common Auto and Allo Challenges and Technical Solutions Common aims of Payers Manufacturing …

Understanding the path needed to bring your cell therapy to market

Robert A. Preti, PhD, President, PCT; Chief Science Officer, NBS joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress ‘Understanding the path needed to bring your cell therapy to market.’ Download this presentation now to find out: What problem are we trying to solve? Development by Design (DbD) Quality by Design (QbD) Assembling a commercial manufacturing …

Neural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals

Richard Garr, President and Chief Executive Officer, Neuralstem joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present on ‘Neural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals.’ Download this presentation now to find out: Technology –Cells Nurturing, Supporting and Rescuing Remaining Neurons Platform- Cell Therapeutics’ Commercialization and Platform Roll-out Small Molecule Drug Program MDD 1b …